{
    "nct_id": "NCT06163898",
    "official_title": "A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma",
    "inclusion_criteria": "Participant has a history of RRMM, and must:\n\n* Part A: Have previously received ≥ 3 prior lines of anti-myeloma therapy.\n* Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "• Must not have previously received alnuctamab or mezigdomide.\n\nNote: Other protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}